Literature DB >> 19399415

Expression of phosphorylated-STAT3 and osteopontin and their correlation in melanoma.

Yan Wu1, Ping Jiang, Yun Lin, Siyuan Chen, Nengxing Lin, Jiawen Li.   

Abstract

The expressions of p-STAT3 and osteopontin in 22 cases of normal nevi and 43 cases of malignant melanoma were immunohistochemically detected, and the correlation between p-STAT3 and osteopontin in malignant melanoma and the correlations of p-STAT3 (or osteopontin) with invasion, metastasis and thickness of malignant melanoma were examined. The results showed p-STAT3 was expressed in 2 of 22 cases of normal nevi and 30 of 43 cases of malignant melanoma, while osteopontin was expressed in 3 cases of normal nevi and 29 cases of malignant melanoma. The expressions of p-STAT3 and osteopontin in melanoma were significantly higher than that in benign nevi. There existed significant correlations between the expression of p-STAT3 and that of osteopontin in melanoma. Furthermore, the expression rates of p-STAT3 were significantly higher in invasive or metastatic melanomas than that their non-invasive or non-metastatic counterparts, and the expression rates of osteopontin were significantly higher in invasive melanomas than that in non-invasive ones. It is concluded that p-STAT3 and osteopontin may play important roles in the pathogenesis of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399415     DOI: 10.1007/s11596-009-0223-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  20 in total

Review 1.  STAT proteins and transcriptional responses to extracellular signals.

Authors:  C M Horvath
Journal:  Trends Biochem Sci       Date:  2000-10       Impact factor: 13.807

2.  The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia.

Authors:  Sheau-Fang Yang; Shyng-Shiou F Yuan; Yao-Tsung Yeh; Ming-Tsang Wu; Jinu-Huang Su; Sz-Chi Hung; Chee-Yin Chai
Journal:  Gynecol Oncol       Date:  2005-09       Impact factor: 5.482

3.  Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells.

Authors:  S Philip; A Bulbule; G C Kundu
Journal:  J Biol Chem       Date:  2001-09-19       Impact factor: 5.157

4.  Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.

Authors:  Satoshi Inoue; Cynthia D Branch; Gary E Gallick; Sunil Chada; Rajagopal Ramesh
Journal:  Mol Ther       Date:  2005-10       Impact factor: 11.454

Review 5.  Vascular endothelial growth factor and osteopontin in tumor biology.

Authors:  N Shijubo; T Uede; S Kon; M Nagata; S Abe
Journal:  Crit Rev Oncog       Date:  2000

Review 6.  Targeting STAT3 affects melanoma on multiple fronts.

Authors:  Marcin Kortylewski; Richard Jove; Hua Yu
Journal:  Cancer Metastasis Rev       Date:  2005-06       Impact factor: 9.264

7.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis.

Authors:  Tong-Xin Xie; Daoyan Wei; Mingguang Liu; Allen C Gao; Francis Ali-Osman; Raymond Sawaya; Suyun Huang
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

8.  Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.

Authors:  Goutam Chakraborty; Shalini Jain; Gopal C Kundu
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

9.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

Authors:  D R Senger; S R Ledbetter; K P Claffey; A Papadopoulos-Sergiou; C A Peruzzi; M Detmar
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

Review 10.  Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos
Journal:  Anticancer Res       Date:  1989 Sep-Oct       Impact factor: 2.480

View more
  5 in total

1.  Osteopontin (OPN) isoforms, diabetes, obesity, and cancer; what is one got to do with the other? A new role for OPN.

Authors:  Konrad Sarosiek; Elizabeth Jones; Galina Chipitsyna; Mazhar Al-Zoubi; Christopher Kang; Shivam Saxena; Ankit V Gandhi; Jocelyn Sendiky; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2015-01-13       Impact factor: 3.452

2.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

3.  Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells.

Authors:  Zhanquan Shi; Mana Mirza; Bo Wang; Michael A Kennedy; Georg F Weber
Journal:  Cancer Lett       Date:  2013-10-22       Impact factor: 8.679

4.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

5.  EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma.

Authors:  Guangtong Deng; Furong Zeng; Yi He; Yu Meng; Huiyan Sun; Juan Su; Shuang Zhao; Yan Cheng; Xiang Chen; Mingzhu Yin
Journal:  Clin Transl Med       Date:  2022-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.